Valorization of lignocellulosic wastes for sustainable xylanase production from locally isolated Bacillus subtilis exploited for xylooligosaccharides’ production with potential antimicrobial activity
There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.
Abstract
The worldwide availability of lignocellulosic wastes represents a serious environmental
challenge with potential opportunities. Xylanases are crucial in lignocellulosic bio-hydrolysis,
but the low enzyme productivity and stability are still challenges. In the current
study,
Bacillus subtilis (coded ARSE2) revealed potent xylanase activity among other local isolates. The enzyme
production optimization revealed that maximum enzyme production (490.58 U/mL) was
achieved with 1% xylan, 1.4% peptone, and 5% NaCl at 30 °C and pH 9. Furthermore,
several lignocellulosic wastes were exploited for sustainable xylanase production,
where sugarcane bagasse (16%) under solid-state fermentation and woody sawdust (2%)
under submerged fermentation supported the maximum enzyme titer of about 472.03 and
485.7 U/mL, respectively. The partially purified enzyme revealed two protein bands
at 42 and 30 kDa. The partially purified enzyme revealed remarkable enzyme activity
and stability at 50–60 °C and pH 8–9. The enzyme also revealed significant stability
toward tween-80, urea, DTT, and EDTA with
Vmax and
Km values of 1481.5 U/mL and 0.187 mM, respectively. Additionally, the purified xylanase
was applied for xylooligosaccharides production, which revealed significant antimicrobial
activity toward
Staphylococcus aureus with lower activity against
Escherichia coli. Hence, the locally isolated
Bacillus subtilis ARSE2 could fulfill the xylanase production requirements in terms of economic production
at a high titer with promising enzyme characteristics. Additionally, the resultant
xylooligosaccharides revealed a promising antimicrobial potential, which paves the
way for other medical applications.
Summary Background Antimicrobial resistance (AMR) poses a major threat to human health around the world. Previous publications have estimated the effect of AMR on incidence, deaths, hospital length of stay, and health-care costs for specific pathogen–drug combinations in select locations. To our knowledge, this study presents the most comprehensive estimates of AMR burden to date. Methods We estimated deaths and disability-adjusted life-years (DALYs) attributable to and associated with bacterial AMR for 23 pathogens and 88 pathogen–drug combinations in 204 countries and territories in 2019. We obtained data from systematic literature reviews, hospital systems, surveillance systems, and other sources, covering 471 million individual records or isolates and 7585 study-location-years. We used predictive statistical modelling to produce estimates of AMR burden for all locations, including for locations with no data. Our approach can be divided into five broad components: number of deaths where infection played a role, proportion of infectious deaths attributable to a given infectious syndrome, proportion of infectious syndrome deaths attributable to a given pathogen, the percentage of a given pathogen resistant to an antibiotic of interest, and the excess risk of death or duration of an infection associated with this resistance. Using these components, we estimated disease burden based on two counterfactuals: deaths attributable to AMR (based on an alternative scenario in which all drug-resistant infections were replaced by drug-susceptible infections), and deaths associated with AMR (based on an alternative scenario in which all drug-resistant infections were replaced by no infection). We generated 95% uncertainty intervals (UIs) for final estimates as the 25th and 975th ordered values across 1000 posterior draws, and models were cross-validated for out-of-sample predictive validity. We present final estimates aggregated to the global and regional level. Findings On the basis of our predictive statistical models, there were an estimated 4·95 million (3·62–6·57) deaths associated with bacterial AMR in 2019, including 1·27 million (95% UI 0·911–1·71) deaths attributable to bacterial AMR. At the regional level, we estimated the all-age death rate attributable to resistance to be highest in western sub-Saharan Africa, at 27·3 deaths per 100 000 (20·9–35·3), and lowest in Australasia, at 6·5 deaths (4·3–9·4) per 100 000. Lower respiratory infections accounted for more than 1·5 million deaths associated with resistance in 2019, making it the most burdensome infectious syndrome. The six leading pathogens for deaths associated with resistance (Escherichia coli, followed by Staphylococcus aureus, Klebsiella pneumoniae, Streptococcus pneumoniae, Acinetobacter baumannii, and Pseudomonas aeruginosa) were responsible for 929 000 (660 000–1 270 000) deaths attributable to AMR and 3·57 million (2·62–4·78) deaths associated with AMR in 2019. One pathogen–drug combination, meticillin-resistant S aureus, caused more than 100 000 deaths attributable to AMR in 2019, while six more each caused 50 000–100 000 deaths: multidrug-resistant excluding extensively drug-resistant tuberculosis, third-generation cephalosporin-resistant E coli, carbapenem-resistant A baumannii, fluoroquinolone-resistant E coli, carbapenem-resistant K pneumoniae, and third-generation cephalosporin-resistant K pneumoniae. Interpretation To our knowledge, this study provides the first comprehensive assessment of the global burden of AMR, as well as an evaluation of the availability of data. AMR is a leading cause of death around the world, with the highest burdens in low-resource settings. Understanding the burden of AMR and the leading pathogen–drug combinations contributing to it is crucial to making informed and location-specific policy decisions, particularly about infection prevention and control programmes, access to essential antibiotics, and research and development of new vaccines and antibiotics. There are serious data gaps in many low-income settings, emphasising the need to expand microbiology laboratory capacity and data collection systems to improve our understanding of this important human health threat. Funding Bill & Melinda Gates Foundation, Wellcome Trust, and Department of Health and Social Care using UK aid funding managed by the Fleming Fund.
Publisher:
Springer Berlin Heidelberg
(Berlin/Heidelberg
)
ISSN
(Print):
0302-8933
ISSN
(Electronic):
1432-072X
Publication date
(Electronic):
21
August
2023
Publication date PMC-release: 21
August
2023
Publication date
(Print):
2023
Volume: 205
Issue: 9
Electronic Location Identifier: 315
Affiliations
[1
]GRID grid.420020.4, ISNI 0000 0004 0483 2576, Bioprocess Development Department, , Genetic Engineering and Biotechnology Research Institute, City of Scientific Research
and Technological Applications (SRTA-City), ; New Borg El-Arab City, Alexandria, 21934 Egypt
Open Access This article is licensed under a Creative Commons Attribution 4.0 International License,
which permits use, sharing, adaptation, distribution and reproduction in any medium
or format, as long as you give appropriate credit to the original author(s) and the
source, provide a link to the Creative Commons licence, and indicate if changes were
made. The images or other third party material in this article are included in the
article's Creative Commons licence, unless indicated otherwise in a credit line to
the material. If material is not included in the article's Creative Commons licence
and your intended use is not permitted by statutory regulation or exceeds the permitted
use, you will need to obtain permission directly from the copyright holder. To view
a copy of this licence, visit
http://creativecommons.org/licenses/by/4.0/.
History
Date
received
: 15
January
2023
Date
revision received
: 21
June
2023
Date
accepted
: 30
July
2023
Funding
Funded by: City of Scientific Research and Technological Applications (SRTA City)
Open Access
:
Open access funding provided by The Science, Technology & Innovation Funding Authority
(STDF) in cooperation with The Egyptian Knowledge Bank (EKB).
scite shows how a scientific paper has been cited by providing the context of the citation, a classification describing whether it supports, mentions, or contrasts the cited claim, and a label indicating in which section the citation was made.